Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Xavier Leleu et al.|The Lancet|2019Cited by 635
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaHang Quach, H. Miles Prince, David Ritchie et al.|Leukemia|2009Cited by 586
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji Kumar, Philippe Moreau, Simon J. Harrison et al.|The Lancet Oncology|2020Cited by 401
Clinical Studies of Histone Deacetylase InhibitorsH. Miles Prince, Simon J. Harrison, Mark Bishton|Clinical Cancer Research|2009Cited by 356